Part 1: Cohort 1: Participants receiving VH4524184 DL1 for Human Immunodeficiency Virus (HIV) Infection
Study Summary
This trial tests a new drug to see if it's safe and how it affects the body, with the potential to modify how other drugs work.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
32 Primary · 3 Secondary · Reporting Duration: Baseline (Day 1) and up to 6.5 weeks
Trial Safety
Safety Progress
Trial Design
19 Treatment Groups
Part 1: Cohort 1: Participants receiving VH4524184 DL1
1 of 19
Part 1: Cohort 3: Participants receiving VH4524184 DL3
1 of 19
Part 1: Cohort 4: Participants receiving VH4524184 DL4
1 of 19
Part 3: Cohort 10: VH4524184 Fasted/ VH4524184 Fed
1 of 19
Part 1: Cohort 2: Participants receiving VH4524184 DL2
1 of 19
Part 1: Cohort 6: Participants receiving VH4524184 DL6
1 of 19
Part 2: Cohort 8: Participants receiving VH4524184 RL2
1 of 19
Part 2: Cohort 9: Participants receiving VH4524184 RL3
1 of 19
Part 2: Cohort 7: Participants receiving VH4524184 RL1
1 of 19
Part 1: Cohort 5: Participants receiving VH4524184 DL5
1 of 19
Part 1: Cohort 6: Participants receiving Placebo
1 of 19
Part 2: Cohort 9: Participants receiving Placebo
1 of 19
Part 1: Cohort 2: Participants receiving Placebo
1 of 19
Part 1: Cohort 4: Participants receiving Placebo
1 of 19
Part 1: Cohort 5: Participants receiving Placebo
1 of 19
Part 2: Cohort 7: Participants receiving Placebo
1 of 19
Part 1: Cohort 3: Participants receiving Placebo
1 of 19
Part 1: Cohort 1: Participants receiving Placebo
1 of 19
Part 2: Cohort 8: Participants receiving Placebo
1 of 19
Experimental Treatment
Non-Treatment Group
105 Total Participants · 19 Treatment Groups
Primary Treatment: Part 1: Cohort 1: Participants receiving VH4524184 DL1 · Has Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 50 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
Pennsylvania | 100.0% |
What site did they apply to?
GSK Investigational Site | 100.0% |
What portion of applicants met pre-screening criteria?
Met criteria | 100.0% |
Frequently Asked Questions
Is the age requirement for this study inclusive of individuals aged 50 and above?
"This medical trial is seeking patients aged 18 to 50 years old." - Anonymous Online Contributor
What potential risks are associated with taking VH4524184 DL1 for individuals?
"The safety of Part 1: Cohort 1: Participants receiving VH4524184 DL1 is assumed to be low, and scored a one due to the limited clinical data present during Phase 1 trials suggesting efficacy or safety." - Anonymous Online Contributor
How many participants have enrolled in this experiment?
"Affirmative. Data hosted on clinicaltrials.gov states that this medical study, which was initially posted on December 2nd 2022, is presently searching for participants. 105 patients must be recruited from one single location to fulfill the requirements of the trial." - Anonymous Online Contributor
Does this experiment have any open slots for volunteers?
"Affirmative. Per the clinicaltrials.gov listing, this trial is open for recruitment of 105 patients from a single medical centre. It was initially posted on December 2nd 2022 and last updated on January 11th 2023." - Anonymous Online Contributor
For whom is this clinical research available?
"This scientific inquiry is in search of 105 individuals that are living with Human Immunodeficiency Virus (HIV) and aged between 18 to 50. For prospective candidates to be considered, they must meet the following criteria: chronological age from 18-50 years old, healthily functioning bodies that weight at least 110 lbs for males or 99 lbs for females along with a Body Mass Index within a range of 18.5 - 32 kg/m^2 respectively; male participants have no contraceptive restrictions while female applicants need to not be expecting, lactating nor physically capable of bearing children." - Anonymous Online Contributor